Visugromab combined with nivolumab showed a median duration of response exceeding two years in refractory NSCLC, UC, and HCC patients. GDF-15 is a therapeutic target and immune escape mechanism, ...
Relmada Therapeutics is advancing NDV-01, a novel intravesical therapy for NMIBC, into phase 3 clinical trials, with Max ...
A significant communication gap exists between NMIBC patients and providers, with only 18% having regular discussions about ...
The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab vedotin-ejfv ...
(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...
The Food and Drug Administration approved Merck's Keytruda in combination with Padcev to treat certain adults with muscle invasive bladder cancer (MIBC).
Pfizer (PFE) and Astellas Pharma (ALPMY) (ALPMY announced that the U.S. Food and Drug Administration has approved PADCEV, a Nectin-4 directed ...
Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...
Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a value of USD 294.4 Billion by 2035 at a CAGR (Compound Annual Growth Rate) of 8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback